Table 2.

Clinical characteristics of the 12 patients treated with chemotherapy

PatientAge (y)GenderPerformance statusWeight loss (kg/mo)TNM classificationPathologic subtypeChemotherapyResponse to this chemotherapy
160M1−3cT2N3M1NSCLC (unknown)Weekly CBDCA+PTXSD
265M0−1cT3N2M1AdenocarcinomaWeekly CBDCA+PTXSD
339M0−4cT4N2M1AdenocarcinomaWeekly CBDCA+PTXSD
451M0−1cT4N3M1Large cellWeekly CBDCA+PTXPR
552F2−1.5cT4N3M1Squamous cellWeekly CBDCA+PTXPD
649M0±0pT2N2M0Large cellWeekly CBDCA+PTXNE
748M0±0cT4N3M1AdenocarcinomaWeekly CBDCA+PTXSD
873M0−1cT4N2M0Squamous cellVNR+UFTSD
976F0±0pT2N2M0AdenocarcinomaWeekly CBDCA+PTXSD
1068M0−4cT3N0M1AdenocarcinomaWeekly CBDCA+PTXSD
1170M0±0cT2N3M0NSCLC (unknown)CDDP+DOCSD
1262M1−1cT4N3M1Squamous cellCBDCA+PTXPD
  • Abbreviations: TNM, tumor-node-metastasis; M, male; F, female; CBDCA, carboplatin; PTX, paclitaxel; VNR, vinorelbine; UFT, tegafur-uracil; CDDP, cisplatin; DOC, docetaxel; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable.